跳至主要内容
临床试验/EUCTR2021-006398-41-Outside-EU/EEA
EUCTR2021-006398-41-Outside-EU/EEA进行中(未招募)1 期

A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan

Eisai Co., Ltd.0 个研究点开始时间: 2022年1月27日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Subjects with with relapsed or refractory follicular lymphoma with EZH2 gene mutation.
  • 2. Subjects treated with tazemetostat.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 1
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 44
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 100

排除标准

  • 1. Subjects with a history of hypersensitivity to any ingredient of Tazverik.

研究者

相似试验